Alzamend Neuro Announces Full Data Set From Its Nonclinical Study: Comparing Brain and Plasma Lithium Exposures Between AL001 and Lithium Carbonate in Alzheimer's Transgenic Mice

Businesswire11/19 21:00

EXCLUSIVE: Alzamend Neuro Reveals Full Data From Nonclinical Study Of Its Lead Alzheimer's Drug Potential

Benzinga11/19 20:30

Ascendiant Capital Maintains Buy on Alzamend Neuro, Lowers Price Target to $35

Benzinga11/11 17:35

Alzamend Neuro Analyst Ratings

Benzinga11/11 17:33

EXCLUSIVE: Alzamend Neuro Reveals Full Data Set From Multiple Ascending Dose Trial For Lead Candidate For Dementia Related to Alzheimer's

Benzinga10/16 19:30

EXCLUSIVE: Alzamend Neuro Tells Benzinga 'Identified Dose Is Unlikely to Require Lithium Therapeutic Drug Monitoring'

Benzinga10/16 19:30